Intermountain Healthcare and Asia Genomics have announced collaboration for Asia Genomics to distribute a test in Southeast Asia that delivers personalized medicine. Officials from both companies finalized an agreement where Asia Genomics now contracts with Intermountain Precision Genomics to offer ICG100™ testing. Intermountain Precision Genomics ICG100™ test is Next Generation Sequencing (NGS) that identifies mutations within a person’s cancer to identify specific DNA targets for personalized drug treatments. Currently approved for late stage cancer patients who have failed a traditional treatment method, the ICG100™ test offers new hope where traditional treatments fall short.
Asia Genomics has been offering various types of genomic tests in the healthcare environment since 2014. The primary focus of the tests Asia Genomics offers center on reproductive health and cancer care. “We are excited to be the first value-adding partner with Intermountain Precision Genomics outside of the U.S. Leveraging Intermountain Precision Genomics’ years of experience in cancer research, diagnosis and treatment, we aim to improve survival and quality of life for cancer patients in Asia”, said Dr. Wong Mun-Yew, CEO & Founder of Asia Genomics. “With this partnership, Asia Genomic continues to stay on the forefront of clinical genomics in Southeast Asia, offering the widest range of curated genomics tests and services.”
“We are pleased to partner with Asia Genomics to help extend life and improve quality of life for late-stage cancer patients across Southeast Asia,” said Terri Kane, Vice President of Intermountain Healthcare’s Southwest Region, which includes Intermountain Precision Genomics. “Targeted therapies are the most effective treatment for late-stage cancer patients and we look forward to this partnership positively impacting the way patients receive care around the world.”